Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23144545 | 0.86 | GPR119 (0.54) | GPR119 | |
| SCHEMBL1089500 | 0.84 | HPGD (0.46) | HPGDGPR119USP30RECQLEPHX1 | |
| SCHEMBL16415863 | 0.84 | EPHX1 (0.51) | HPGDGPR119USP30RECQLEPHX1 | |
| SCHEMBL16409534 | 0.82 | GPR119 (0.44) | HPGDGPR119USP30RECQLEPHX1 | |
| SCHEMBL1827484 | 0.82 | HPGD (0.51) | HPGDGPR119USP30RECQLEPHX1 | |
| SCHEMBL27108296 | 0.82 | GPR119 (0.47) | HPGDGPR119USP30RECQLEPHX1 | |
| SCHEMBL7754719 | 0.81 | USP30 (0.45) | HPGDGPR119USP30RECQLEPHX1 | |
| SCHEMBL19026787 | 0.81 | GPR119 (0.52) | HPGDGPR119USP30RECQLEPHX1 | |
| SCHEMBL23144561 | 0.80 | RECQL (0.52) | GPR119RECQLUSP2SMN1; SMN2 | |
| SCHEMBL4711418 | 0.80 | HPGD (0.55) | HPGDGPR119USP30RECQLEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111925367-B | Fused ring derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-111925367-A | Fused ring derivative inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2020-11-13 | — | — | CN | disclosed |
| US-20160166560-A1 | Urea Compounds and Their Use as FAAH Enzyme Inhibitors | BIAL-PORTELA & CA, S.A. (PT) | 2016-06-16 | — | — | US | disclosed |
| US-20160166560-A1 | Urea Compounds and Their Use as FAAH Enzyme Inhibitors | BIAL-PORTELA & CA, S.A. (PT) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166560-A1 | Urea Compounds and Their Use as FAAH Enzyme Inhibitors | FAAH, FAAH2, HRH2 | HPGD 491/4885GPR119 436/4885USP30 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.